Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2010

View Archived Issues

Daiichi Sankyo reports third quarter 2009 reults

Kyowa Hakko Kirin reports third quarter 2009 results

Promising data disclosed on TNFerade for esophageal cancer

Phase II data show everolimus monotherapy to be safe and active in metastatic gastric cancer

First phase I trial of KRN-330 supports safety and tolerability in advanced CRC

Abbott presents novel analgesic agents

Vyvanse available in Canada for ADHD

Biomolecular Pharma presents antiviral agents for treatment of neural measles infection

Pfizer claims CRF1 receptor antagonists for treatment of female sexual disorders

Albany Molecular Research describes 5-HT3 receptor modulators for IBS therapy

Combination of pasireotide and everolimus feasible for neuroendocrine tumors

Wyeth identifies mGlu5 receptor antagonists as anxiolytics

Concert Pharmaceuticals claims novel HIV protease inhibitors

Ligand acquires Metabasis

Rilotumumab dose selected for randomized evaluation with panitumumab in mCRC

Zelos Therapeutics initiates dosing in phase I nasal spray teriparatide trial

Idera initiates phase I IMO-3100 trial for autoimmune disease indications

FDA expands use of GlaxoSmithKline's Tykerb in breast cancer

Stem Cell receives No Objection Letter from Health Canada for phase IIa trial

Allon initiates trial to expand safety profile for davunetide

Starpharma and Lilly sign new drug delivery collaboration

QuantRx Biomedical to acquire NuRx

FDA approves once-a-day Lamictal XR as add-on epilepsy therapy

Algeta initiates treatment in phase II clinical trial of Alpharadin in breast cancer

Leo Pharma reports results from phase III study of PEP-005 for treatment of AK lesions

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...